Interní Med. 2008; 10(2): 80-83

Pharmacotherapy of immunopathological reactions - suppression of adverse reactions

PharmDr. Petr Jílek CSc
Farmaceutická fakulta, katedra biologických a lékařských věd, Hradec Králové

Inadequate immune reactions against agents from environment could be found as allergies, while unregulated reactivity against self-structures is known as autoimmune disease. Many drugs are available for treatment of such disorders. Most frequently drugs suppressing the immune reactions on the level of intercellular signaling pathways as well as in the effector phase of pathological processes are used. Methods re-inducing the immunological tolerance of target structures of autoaggressivity are promising. Immunosuppressants bring the risk of impairment of antimicrobial and anticancer resistance.

Keywords: antihistamines, antileukotriens, hyposensibilization, glucocorticoids, cytostatics, anticytokines

Published: May 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jílek P. Pharmacotherapy of immunopathological reactions - suppression of adverse reactions. Interní Med. 2008;10(2):80-83.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Andreakos ET, Foxwell BM, Brennan FM, Maini RN, Feldmann M. Cytokines and anti-cytokine biologicals in autoimmunity: present and future. Cytokine Growth Factor Rev 2002; 13 (4-5): 299-313. Go to original source... Go to PubMed...
    2. Curotto de Lafaille MA, Lafaille JJ. CD4 (+) regulatory T cells in autoimmunity and allergy. Curr Opin Immunol 2002; 14 (6): 771-778. Go to original source... Go to PubMed...
    3. Dambrin C, Klupp J, Morris RE. Pharmacodynamics of immunosuppressive drugs. Curr Opin Immunol 2000; 12 (5): 557-562. Go to original source... Go to PubMed...
    4. Hakim FT, Flomerfelt FA, Boyiadzis M, Gress RE. Aging, immunity and cancer. Curr Opin Immunol 2004; 16 (2): 151-156. Go to original source... Go to PubMed...
    5. Herrmann ML, Schleyerbach R, Kirschbaum BJ. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology 2000; 47 (2-3): 273-289. Go to original source... Go to PubMed...
    6. Kitahara K, Kawai S. Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr Opin Rheumatol 2007; 19 (3): 238-245. Go to original source... Go to PubMed...
    7. Meagher LJ, Wines NY, Cooper AJ. Atopic dermatitis: review of immunopathogenesis and advances in immunosuppressive therapy. Australas J Dermatol 2002; 43 (4): 247-254. Go to original source... Go to PubMed...
    8. Ng SC, Arebi N, Kamm MA. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm Bowel Dis 2007; 13 (2): 129-134. Go to original source... Go to PubMed...
    9. Norambuena RX, Mallol J, Rios MG, Quevedo RF, Quezada LA. Therapeutic effects of the anti-tumor necrosis factor monoclonal antibody, infliximab, in four children with refractory juvenile idiopathic arthritis. Allergol Immunopathol (Madr) 2007; 35 (2): 52-56. Go to original source... Go to PubMed...
    10. Padgett DA, Glaser R. How stress influences the immune response. Trends Immunol 2003; 24 (8): 444-448. Go to original source... Go to PubMed...
    11. Rolland JM, Douglass J, O' Hehir RE. Allergen immunotherapy: current and new therapeutic strategies. Expert Opin Investig Drugs 2000; 9 (3): 515-527. Go to original source... Go to PubMed...
    12. Rolny P, Sadik R. Longer term outcome of steroid refractory ulcerative colitis treated with intravenous cyclosporine without subsequent oral cyclosporine maintenance therapy. Int J Colorectal Dis 2002; 17 (2): 67-69. Go to original source... Go to PubMed...
    13. Simpson D, Noble S. Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions. Drugs 2005; 65 (6): 827-858. Go to original source... Go to PubMed...
    14. Vial T, Choquet Kastylevsky G, Descotes J. Adverse effects of immunotherapeutics involving the immune system. Toxicology 2002; 174 (1): 3-11. Go to original source... Go to PubMed...
    15. Von Hertzen LC, Haahtela T. Asthma and atopy - the price of affluence? Allergy 2004; 59 (2): 124-137. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.